Please login to the form below

Not currently logged in
Email:
Password:

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

Royalty PharmaFresh from negotiating a $3.25bn windfall from partner Biogen Idec, Elan has become the target of a possible takeover bid by US company Royalty Pharma.

Privately-held Royalty Pharma specialises in buying up intellectual property assets in the pharma sector, generating revenues from royalty interests in more than 30 approved or late-stage drugs.

The company's move for Elan comes after the Irish drugmaker signed over rights to multiple sclerosis therapy Tysabri (natalizumab) to Biogen Idec in a deal that netted it $3.25bn upfront and a royalty steam.

Elan has already said it would return $1bn to shareholders and refinance debt, with analysts suggesting that a push for liquidity meant some form of merger or acquisition may be on the cards.

Royalty Pharma said in a statement issued this morning that it met with Elan's management last week to propose a $11-per-share offer for the pharma company - a 12.5 per cent premium to its closing price on February 15 - and was "surprised" that Elan's subsequent statement about the Biogen Idec deal had made no mention of its approach.

The offer would value Elan at more than $6bn but is only around 4 per cent higher than the company's closing share price last Friday of $10.58.

The company said it was effectively offering Elan shareholders a "simple and clear choice": remain an investor in a company whose material assets will consist of cash and Tysabri royalties while management looks for other opportunities, or sell for a cash amount.

"The risks and lack of earnings visibility associated with Elan's acquisition and in-licensing strategy are substantial," claims Royalty Pharma in its proposal document, which stresses this is not yet a firm intention to make an offer.

At the time of writing Elan had not yet responded publicly to the proposal statement from Royalty Pharma.

25th February 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics